FDA Will Solicit sNDAs For Well-Researched Off-Label Uses, Gottlieb Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency’s move is a reaction to the potentially decreased importance of registration due to adequate off-label reimbursement.
You may also be interested in...
Access To Investigational Drugs Under FDA Proposed Rule Depends On Size Of Treatment Group
Agency also details criteria for charging for investigational drugs in separate proposed rule.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.